MRK

Company overview

Merck is a global pharmaceutical company best known for Keytruda, one of the best selling cancer drugs in the world. It also has a large vaccine business, an animal health division, and a pipeline aimed at diversifying revenue beyond its top oncology product.

Business model

Merck earns most of its money from prescription drugs sold to hospitals, pharmacies, and health systems worldwide, with Keytruda representing a large share of total revenue. Vaccines and animal health provide steadier, less concentrated income streams alongside the drug business.

Growth drivers

• Continued expansion of Keytruda into new cancer indications
• New oncology and cardiovascular pipeline approvals
• Growth in the animal health segment
• Vaccine demand in international markets

Competitive position

Merck's scale, sales infrastructure, and research budget let it compete across many therapeutic areas at once. Its oncology franchise has strong physician trust and a wide base of approved uses, which supports durable demand even as competitors enter the market.

Risks

Keytruda faces patent expiration later this decade, and the size of that single product concentration is the central risk to the story. Pipeline execution, pricing pressure, and biosimilar competition could all weigh on results if new products don't scale in time.

Valuation

Merck typically trades at a discount to peers because of the looming patent cliff. That discount can be reasonable or overdone depending on how convincing the pipeline replacement story looks at any given time.

Final view

Overall rating: 68/100

Merck is a well run pharmaceutical company with a genuine near term risk in Keytruda's patent timeline. My view is that the company is investable at the right price, but the pipeline needs to prove it can replace that revenue before the discount fully closes.